Ensayos que prueban un tratamiento · 7 estudios
Aquí se prueba algo nuevo: un medicamento, una pauta o un procedimiento. Si participas, recibes el tratamiento en estudio o el estándar, y el equipo te sigue de cerca.
Leucemia linfocítica crónica o linfoma linfocítico de células pequeñas en recaída: pirtobrutinib
The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The purpose of Part 2 of this study is to evaluate pirtobrutinib monotherapy in participants with treatment-naïve CLL/SLL with 17p deletions. Participation in Part 1 is expected to last approximately 3 years. Participation in Part 2 is expected to last up to 2 years.
Para: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
5 centros: Fundeni Clinical Institute, București · Institutul Oncologic Cluj, Cluj-Napoca · Spitalul Clinic Municipal Filantropia Craiova, Craiova · y 2 más
Fase 2Ver la ficha oficial ↗NCT06588478
Título original del registro
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Cánceres de la sangre: nemtabrutinib, un medicamento en estudio
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).
Para: Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
4 centros: Centrul de Diagnostic si Tratament Oncologic Brasov, Brașov · Spitalul Clinic Colțea, București · Institutul Regional de Oncologie Iasi, Iași · y 1 más
Fase 2Ver la ficha oficial ↗NCT04728893
Título original del registro
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Linfoma difuso de células B grandes sin tratamiento previo: zilovertamab vedotin en lugar de la vincristina del esquema clásico
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
Para: Diffuse Large B-Cell Lymphoma
4 centros: Centrul de Diagnostic si Tratament Oncologic Brasov, Brașov · Spitalul Clinic Colțea, București · Institutul Oncologic Cluj, Cluj-Napoca · y 1 más
Fase 3Ver la ficha oficial ↗NCT06717347
Título original del registro
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Leucemia linfocítica crónica o linfoma linfocítico de células pequeñas: APG2575, un medicamento en estudio
This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors
Para: CLL/SLL
3 centros: București · Cluj-Napoca · Timișoara
Fase 3Ver la ficha oficial ↗NCT06104566
Título original del registro
Global Trial in APG2575 for Patients With CLL/SLL
Leucemia linfocítica crónica o linfoma linfocítico de células pequeñas en recaída: BGB-16673 comparado con pirtobrutinib
The purpose of this study is to evaluate the efficacy and safety of tacabrutideg alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had been previously treated with a covalent Bruton tyrosine kinase inhibitor (cBTKi).
Para: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
3 centros: Coltea Clinical Hospital, București · Institutul Oncologic Prof Dr Ion Chiricuta Cluj Napoca, ClujNapoca · Institutul Regional de Oncologie Iasi, Iași
Fase 3Ver la ficha oficial ↗NCT06973187
Título original del registro
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Linfoma difuso de células B grandes en recaída o refractario: una vacuna terapéutica junto con pembrolizumab
This is a Phase 2b, randomized, open label study to assess the safety and efficacy of DPX-Survivac and pembrolizumab, with and without low-dose cyclophosphamide (CPA) in subjects with relapsed or refractory DLBCL.
Para: Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
2 centros: Bucharest Oncology Institute "Prof.Dr.Al. Trestioreanu", București · The Oncology Institute "Prof. Dr. Ion Chiricuţă" I.O.C.H., Cluj-Napoca
Fase 2Ver la ficha oficial ↗NCT04920617
Título original del registro
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Cánceres de células B maduras: SGR-1505, un medicamento en estudio
The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.
Para: Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia
2 centros: ARENSIA Institutul Oncologic Prof. Dr. Alexandru Trestioreanu Bucuresti, București · ARENSIA Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj Napoca, Cluj-Napoca
Fase 1Ver la ficha oficial ↗NCT05544019
Título original del registro
Study of SGR-1505 in Mature B-Cell Neoplasms
Estudios observacionales · un estudio
Aquí NO recibes un tratamiento nuevo. Sigues con tu atención habitual y los investigadores recogen información sobre cómo va. Es útil para quienes vengan después de ti, pero no cambia tu propia atención.
Registro observacional del linfoma de células T periféricas de nuevo diagnóstico
This study T-Cell Project 2.0 is based on the former International PTCL study designed by the International T-cell Non-Hodgkin's Lymphoma Study Group (T-Cell Project 1.0: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma) as a prospective collection of data to predict the prognosis of patients with the more frequent subtypes of PTCL. It is a prospective, longitudinal, international, observational study of patients with newly diagnosed peripheral T-cell lymphoma aiming to verify whether this prospective collection of data would allow achieving a more accurate information on T-cell lymphomas.
The study aims to better define the clinical relevance of the new WHO Classification, the role of FDG-PET in staging and response assessment, the prognosis of different entities, the genomic landscape of different subtypes, and to investigate on most optimal treatment strategies for these neoplasms in the real-world population as well as molecular markers and to explore the prognostic or predictive implications of them in PTCL.
The study aims to better define the clinical relevance of the new WHO Classification, the role of FDG-PET in staging and response assessment, the prognosis of different entities, the genomic landscape of different subtypes, and to investigate on most optimal treatment strategies for these neoplasms in the real-world population.
Para: Peripheral T-Cell Lymphoma
Un centro: Cluj Napoca_Ion Chiricuta Oncology Institute, Cluj-Napoca
Fase no indicadaVer la ficha oficial ↗NCT03964480
Título original del registro
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.
Fuente: ClinicalTrials.gov, el registro público de la National Library of Medicine de Estados Unidos. Datos obtenidos el 13 oct 2026.
